Please assess the completion status of the following clinical trial:

Trial Title: Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female subjects, aged \<40yr at the time of breast cancer diagnosis~2. Diagnosis of operable breast cancer any T and N, any ER~3. Patients candidate to adjuvant chemotherapy for 4-8 cycles.~4. Patients compliant to adhere to all protocol procedures.~5. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 28 days prior to the start of the study treatment.~6. Negative pregnancy test at the study enrolment; fertile women must use effective contraception during chemotherapy~7. Patients must be able to understand and sign written informed consent.~   -~Exclusion Criteria:~1. Presence of distant metastasis~2. Clinically significant cardiovascular disease~3. Psychological or social conditions which might affect study compliance~4. Unstable neurologic function~5. Patients with known allergy to any of the components of the study medication~6. Pregnancy or lactation~7. Any condition that, in the opinion of the physician is likely to affect inclusion of the subject into the study.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Triptorelin (Type: EXPERIMENTAL): Triptorelin 3.75 administered every 28 days, for 4 to 7 injections depending on the number of cycles of chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).